Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Non Operating Income (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Non Operating Income data on record, last reported at $2.0 million in Q4 2025.

  • For Q4 2025, Non Operating Income rose 131.01% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $8.1 million, up 471.71%, while the annual FY2025 figure was $8.1 million, 5057.67% up from the prior year.
  • Non Operating Income reached $2.0 million in Q4 2025 per CTNM's latest filing, down from $2.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.5 million in Q4 2023 and bottomed at -$6.3 million in Q4 2024.
  • Average Non Operating Income over 3 years is $1.1 million, with a median of $1.9 million recorded in 2025.
  • The widest YoY moves for Non Operating Income: up 7619.44% in 2024, down 281.42% in 2024.
  • A 3-year view of Non Operating Income shows it stood at $3.5 million in 2023, then crashed by 281.42% to -$6.3 million in 2024, then surged by 131.01% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $2.0 million in Q4 2025, $2.1 million in Q3 2025, and $1.9 million in Q2 2025.